Foxl1 inhibits tumor invasion and predicts outcome in human renal cancer

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 1, 2014, Pages 110-122

  Yang, Feng Qiang ^a   Yang, Feng Ping ^b   Li, Wei ^a   Liu, Min ^a   Wang, Guang Chun ^a   Che, Jian Ping ^a   Huang, Jian Hua ^a   Zheng, Jun Hua ^a,b  

^a TONGJI UNIVERSITY   (China)

^b Xinjiang Province   (China)

Author keywords

Clear cell renal cell carcinoma; Foxl1; Prognosis

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; FOXL1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; FEMALE; FOXL1; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION; WESTERN BLOTTING;

CLEAR CELL RENAL CELL CARCINOMA; FOXL1; PROGNOSIS;

ADULT; AGED; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84891691826     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ and Epstein JI. Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int 2010; 60: 1-8.
2. Montironi R, Santinelli A, Pomante R, Mazzucchelli R, Colanzi P, Filho AL and Scarpelli M. Morphometric index of adult renal cell carcinoma. Comparison with the Fuhrman grading system. Virchows Arch 2000; 437: 82-89.
3. Matsuura K, Nakada C, Mashio M, Narimatsu T, Yoshimoto T, Tanigawa M, Tsukamoto Y, Hijiya N, Takeuchi I, Nomura T, Sato F, Mimata H, Seto M and Moriyama M. Downregulation of SAV1 plays a role in pathogenesis of high-grade clear cell renal cell carcinoma. BMC Cancer 2011; 11: 523.
4. Cindolo L, Patard JJ, Chiodini P, Schips L, Ficarra V, Tostain J, de La Taille A, Altieri V, Lobel B, Zigeuner RE, Artibani W, Guille F, Abbou CC, Salzano L and Gallo C. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 2005; 104: 1362-1371.
5. Karakiewicz PI, Briganti A, Chun FK, Trinh QD, Perrotte P, Ficarra V, Cindolo L, De la Taille A, Tostain J, Mulders PF, Salomon L, Zigeuner R, Prayer-Galetti T, Chautard D, Valeri A, Lechevallier E, Descotes JL, Lang H, Mejean A and Patard JJ. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007; 25: 1316-1322.
6. Jiang Z, Chu PG, Woda BA, Liu Q, Balaji KC, Rock KL and Wu CL. Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. Clin Cancer Res 2008; 14: 5579-5584.
7. Patil S, Ishill N, Deluca J and Motzer RJ. Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation. Cancer 2010; 116: 347-354.
8. Hannenhalli S, Kaestner KH. The evolution of Fox genes and their role in development and disease. Nat Rev Genet 2009; 10: 233-240.
9. Roy SK, Srivastava RK and Shankar S. Inhibition of PI3K/AKT and MAPK ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal 2010; 5: 10.
10. Arden KC. FoxOs in tumor suppression and stem cell maintenance. Cell 2007; 128: 235-237.
11. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, Miao L, Tothova Z, Horner JW, Carrasco DR, Jiang S, Gilliland DG, Chin L, Wong WH, Castrillon DH and DePinho RA. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 2007; 128: 309-323.
12. Raychaudhuri P and Park HJ. FoxM1: a master regulator of tumor metastasis. Cancer Res 2011; 71: 4329-4333.
13. Sun HC, Li M, Lu JL, Yan DW, Zhou CZ, Fan JW, Qin XB, Tang HM and Peng ZH. Overexpression of Forkhead box M1 protein associates with aggressive tumor features and poor prognosis of hepatocellular carcinoma. Oncol Rep 2011; 25: 1533-1539.
14. Wang Z, Banerjee S, Kong D, Li Y and Sarkar FH. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 2007; 67: 8293-8300.
15. Bhat UG, Halasi M and Gartel AL. Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PLoS One 2009; 4: e5592.
16. Takano-Maruyama M, Hase K, Fukamachi H, Kato Y, Koseki H and Ohno H. Foxl1-deficient mice exhibit aberrant epithelial cell positioning resulting from dysregulated EphB/EphrinB expression in the small intestine. Am J Physiol Gastrointest Liver Physiol 2006; 291: G163-170.
17. Perreault N, Katz JP, Sackett SD and Kaestner KH. Foxl1 controls the Wnt beta-catenin pathway by modulating the expression of proteoglycans in the gut. J Biol Chem 2001; 276: 43328-43333.
18. Perreault N, Sackett SD, Katz JP, Furth EE and Kaestner KH. Foxl1 is a mesenchymal Modifier of Min in carcinogenesis of stomach and colon. Genes Dev 2005; 19: 311-315.
19. Möller E. EWSR1 and FUS fusion genes in tumorigenesis. Lund University, Faculty of Medicine Doctoral Dissertation Series 2010; 2010.
20. Lynch HT, Smyrk TC. Identifying hereditary non-polyposis colorectal cancer. N Engl J Med 1998; 338: 1537-8.
21. Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I, Todoerti K, Verdelli D, Battaglia C, Bertoni F, Deliliers GL and Neri A. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer 2009; 48: 603-614.
22. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F and Zangari M. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007; 109: 1692-1700.
23. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson KC, Chin L, Shaughnessy JD Jr, Brennan C and Depinho RA. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006; 9: 313-325.
24. Zhang G, He P, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Hanna N, Alexander HR and Hussain SP. FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer. Cancer Res 2013; 73: 5416-5425.
25. Kessenbrock K, Plaks V and Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52-67.
26. Gialeli C, Theocharis AD and Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278: 16-27.
27. Rink M, Chun FK, Robinson B, Sun M, Karakiewicz PI, Bensalah K, Fisch M, Scherr DS, Lee RK, Margulis V and Shariat SF. Tissue-based molecular markers for renal cell carcinoma. Minerva Urol Nefrol 2011; 63: 293-308.
28. Liu Z, Li L, Yang Z, Luo W, Li X, Yang H, Yao K, Wu B and Fang W. Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer 2010; 10: 270.